PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Innovation in Antibody Drug-Conjugate Engineering: Will It Pay Off?
Visit https://www.peervoice.com/SEB860 to view the entire programme with slides. After completing “Innovation in Antibody Drug-Conjugate Engineering: Will It Pay Off?”, participants will be able to: Describe the limitations associated with current cancer therapies and the rationale for advancing antibody drug-conjugate (ADC) technology; Summarise the clinical data for the most advanced emerging ADCs in development for solid tumours; Translate how new-generation ADCs could impact current clinical practice